https://doi.org/10.3269/1970-5492.2012.7.13
IMAGING FINDINGS OF HEPATIC FOCAL NODULAR HYPERPLASIA IN GD-EOB-DTPA VS. GD-BOPTA-ENHANCED MRI
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: January 12 2026
Focal nodular hyperplasia (FNH) is a benign focal lesion of the liver. Magnetic resonance imaging (MRI) plays a key role in the detection and characterization of focal hepatic le- sions, thanks to the widespread availability of conventional contrast media, especially liver-specific media such as Gd-BOPTA (Multihance, or Gadobenate Dimeglumine) and Gd- EOB-DTPA (Primovist, or Gadoxetic Acid) that are selectively accumulated in hepatocytes and partially excreted by the biliary system. There are no significant differences in FNH enhancement, neither during the dynamic phase nor during the liver-specific phase of MRI, following the infusion with GD-BOPTA or GD-EOB-DTPA.
Downloads
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.